What is RoosterBio?
Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio operates as a privately held cell manufacturing platform technology company. Its core mission is to accelerate the development of a sustainable Regenerative Medicine industry. By providing customers with advanced cell manufacturing solutions, RoosterBio aims to streamline the path from research to commercialization, positioning itself as a key enabler in the rapidly evolving biotech landscape. The company's focus on platform technology suggests a scalable model designed to support a diverse range of regenerative medicine applications.
How much funding has RoosterBio raised?
RoosterBio has raised a total of $35.9M across 6 funding rounds:
Private Equity
$5.2M
Debt
$1.3M
Series A
$6M
Series B
$21.5M
Debt
$1M
Debt
$990K
Private Equity (2016): $5.2M, investors not publicly disclosed
Debt (2017): $1.3M, investors not publicly disclosed
Series A (2017): $6M, investors not publicly disclosed
Series B (2019): $21.5M featuring Bioeconomy Capital, Dynamk Capital, and Vanedge Capital
Debt (2020): $1M backed by PPP
Debt (2021): $990K with participation from PPP
Key Investors in RoosterBio
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy. We expect advances in biology to profoundly improve the human condition and contribute to the global economy. Bioeconomy Capital invests primarily in: (i) technologies that enable biological engineering and production; and (ii) companies that use those technologies to produce goods and services.
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies. The firm aims to support innovative companies that are advancing the field of life sciences. Their portfolio includes various companies engaged in cutting-edge research and development in the life sciences sector. Dynamk Capital is dedicated to funding the future of life sciences through strategic investments.
Vanedge Capital
Vanedge Capital is an early-stage venture capital fund based in Vancouver, Canada, focusing on empowering visionary technologists in the Hard Tech and AI & Analytics sectors. The firm leverages its deep domain expertise, operating experience, and extensive network to support exceptional entrepreneurs in scaling their businesses. With over $500 million under management, Vanedge employs a refined investment process to identify technology trends and attract top founders as partners. Their strategy emphasizes mitigating execution risk and attracting follow-on capital from institutional investors for high-growth foundational technology companies.
What's next for RoosterBio?
The recent strategic investment into RoosterBio signals a pivotal moment for the company, likely enabling further expansion of its manufacturing capabilities and market reach. With a clear focus on accelerating the regenerative medicine industry, this capital infusion is expected to fuel innovation in cell therapy development and production. RoosterBio's trajectory suggests a continued emphasis on strategic partnerships and technological advancements to solidify its position as a leader in the cell manufacturing space.
See full RoosterBio company page
